An inflatable balloon catheter and liquid 125I radiation source (GliaSite Radiation Therapy System) for treatment of recurrent malignant glioma: multicenter safety and feasibility trial

Restricted access

Object. In this study the authors evaluated the safety and performance of the GliaSite Radiation Therapy System (RTS) in patients with recurrent malignant brain tumors who were undergoing tumor resection.

Methods. The GliaSite is an inflatable balloon catheter that is placed in the resection cavity at the time of tumor debulking. Low-dose-rate radiation is delivered with an aqueous solution of organically bound iodine-125 (Iotrex [sodium 3-(125I)-iodo-4-hydroxybenzenesulfonate]), which are temporarily introduced into the balloon portion of the device via a subcutaneous port. Adults with recurrent malignant glioma underwent resection and GliaSite implantation. One to 2 weeks later, the device was filled with Iotrex for 3 to 6 days, following which the device was explanted. Twenty-one patients with recurrent high-grade astrocytomas were enrolled in the study and received radiation therapy. There were two end points: 1) successful implantation and delivery of brachytherapy; and 2) safety of the device.

Implantation of the device, delivery of radiation, and the explantation procedure were well tolerated. At least 40 to 60 Gy was delivered to all tissues within the target volume. There were no serious adverse device-related events during brachytherapy. One patient had a pseudomeningocele, one patient had a wound infection, and three patients had meningitis (one bacterial, one chemical, and one aseptic). No symptomatic radiation necrosis was identified during 21.8 patient-years of follow up. The median survival of previously treated patients was 12.7 months (95% confidence interval 6.9–15.3 months).

Conclusions. The GliaSite RTS performs safely and efficiently. It delivers a readily quantifiable dose of radiation to tissue at the highest risk for tumor recurrence.

Article Information

Contributor Notes

Address reprint requests to: Stephen Tatter, M.D., c/o The NABTT CNS Consortium, 1650 Orleans Street, Room G87, Baltimore, Maryland 21231. email: jfisher@jhmi.edu.

© AANS, except where prohibited by US copyright law.

Headings
References
  • 1.

    Akabani GReist CJCokgor Iet al: Dosimetry of 131I-labeled 81C6 monoclonal antibody administered into surgically created resection cavities in patients with malignant brain tumors. J Nucl Med 40:6316381999Akabani G Reist CJ Cokgor I et al: Dosimetry of 131I-labeled 81C6 monoclonal antibody administered into surgically created resection cavities in patients with malignant brain tumors. J Nucl Med 40:631–638 1999

    • Search Google Scholar
    • Export Citation
  • 2.

    Bernstein MLaperriere NGlen Jet al: Brachytherapy for recurrent malignant astrocytoma. Int J Radiat Oncol Biol Phys 30:121312171994Bernstein M Laperriere N Glen J et al: Brachytherapy for recurrent malignant astrocytoma. Int J Radiat Oncol Biol Phys 30:1213–1217 1994

    • Search Google Scholar
    • Export Citation
  • 3.

    Cokgor IAkabani GKuan CTet al: Phase I trial results of iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomas. J Clin Oncol 18:386238722000Cokgor I Akabani G Kuan CT et al: Phase I trial results of iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomas. J Clin Oncol 18:3862–3872 2000

    • Search Google Scholar
    • Export Citation
  • 4.

    Dempsey JFWilliams JAStubbs JBet al: Dosimetric properties of a novel brachytherapy balloon applicator for the treatment of malignant brain-tumor resection-cavity margins. Int J Radiat Oncol Biol Phys 42:4214291998Dempsey JF Williams JA Stubbs JB et al: Dosimetric properties of a novel brachytherapy balloon applicator for the treatment of malignant brain-tumor resection-cavity margins. Int J Radiat Oncol Biol Phys 42:421–429 1998

    • Search Google Scholar
    • Export Citation
  • 5.

    Johannesen TBWatne KLote Ket al: Intracavity fractionated balloon brachytherapy in glioblastoma. Acta Neurochir 141:1271331999Johannesen TB Watne K Lote K et al: Intracavity fractionated balloon brachytherapy in glioblastoma. Acta Neurochir 141:127–133 1999

    • Search Google Scholar
    • Export Citation
  • 6.

    Kaplan ELMeier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:4574811958Kaplan EL Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457–481 1958

    • Search Google Scholar
    • Export Citation
  • 7.

    Laperriere NJLeung PMMcKenzie Set al: Randomized study of brachytherapy in the initial management of patients with malignant astrocytoma. Int J Radiat Oncol Biol Phys 41:100510111998Laperriere NJ Leung PM McKenzie S et al: Randomized study of brachytherapy in the initial management of patients with malignant astrocytoma. Int J Radiat Oncol Biol Phys 41:1005–1011 1998

    • Search Google Scholar
    • Export Citation
  • 8.

    Lee SWFraass BAMarsh LHet al: Patterns of failure following high-dose 3-D conformal radiotherapy for high-grade astrocytomas: a quantitative dosimetric study. Int J Radiat Oncol Biol Phys 43:79881999Lee SW Fraass BA Marsh LH et al: Patterns of failure following high-dose 3-D conformal radiotherapy for high-grade astrocytomas: a quantitative dosimetric study. Int J Radiat Oncol Biol Phys 43:79–88 1999

    • Search Google Scholar
    • Export Citation
  • 9.

    Leibel SAGutin PHDavis RL: Factors affecting radiation injury after interstitial brachytherapy for brain tumors in Gutin PHLeibel SASheline GE (eds): Radiation Injury to the Nervous System. New York: Raven Press1991 pp 257270Leibel SA Gutin PH Davis RL: Factors affecting radiation injury after interstitial brachytherapy for brain tumors in Gutin PH Leibel SA Sheline GE (eds): Radiation Injury to the Nervous System. New York: Raven Press 1991 pp 257–270

    • Search Google Scholar
    • Export Citation
  • 10.

    Ling CCAnderson LLShipley WU: Dose inhomogeneity in interstitial implants using 125I seeds. Int J Radiat Oncol Biol Phys 5: 4194251979Ling CC Anderson LL Shipley WU: Dose inhomogeneity in interstitial implants using 125I seeds. Int J Radiat Oncol Biol Phys 5:419–425 1979

    • Search Google Scholar
    • Export Citation
  • 11.

    McDermott MWGutin PHLarson DAet al: Interstitial brachytherapy. Neurosurg Clin N Am 1:8018241990McDermott MW Gutin PH Larson DA et al: Interstitial brachytherapy. Neurosurg Clin N Am 1:801–824 1990

    • Search Google Scholar
    • Export Citation
  • 12.

    Monroe JIDempsey JFDorton JAet al: Experimental validation of dose calculation algorithms for the GliaSite RTS, a novel 125I liquid-filled balloon brachytherapy applicator. Med Phys 28:73852001Monroe JI Dempsey JF Dorton JA et al: Experimental validation of dose calculation algorithms for the GliaSite RTS a novel 125I liquid-filled balloon brachytherapy applicator. Med Phys 28:73–85 2001

    • Search Google Scholar
    • Export Citation
  • 13.

    Prados MDGutin PHPhillips TLet al: Interstitial brachytherapy for newly diagnosed patients with malignant gliomas: the UCSF experience. Int J Radiat Oncol Biol Phys 24:5935971992Prados MD Gutin PH Phillips TL et al: Interstitial brachytherapy for newly diagnosed patients with malignant gliomas: the UCSF experience. Int J Radiat Oncol Biol Phys 24:593–597 1992

    • Search Google Scholar
    • Export Citation
  • 14.

    Prasad SCBassano DAFear PIet al: Dosimetry of I-125 seeds implanted on the surface of a cavity. Med Dosim 15:2172191990Prasad SC Bassano DA Fear PI et al: Dosimetry of I-125 seeds implanted on the surface of a cavity. Med Dosim 15:217–219 1990

    • Search Google Scholar
    • Export Citation
  • 15.

    Reardon DAAkabani GColeman REet al: Phase II trial of murine 131I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. J Clin Oncol 20:138913972002Reardon DA Akabani G Coleman RE et al: Phase II trial of murine 131I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. J Clin Oncol 20:1389–1397 2002

    • Search Google Scholar
    • Export Citation
  • 16.

    Saw CBSuntharalingam NAyyangar KMet al: Dosimetric considerations of stereotactic brain implants. Int J Radiat Oncol Biol Phys 17:8878911989Saw CB Suntharalingam N Ayyangar KM et al: Dosimetric considerations of stereotactic brain implants. Int J Radiat Oncol Biol Phys 17:887–891 1989

    • Search Google Scholar
    • Export Citation
  • 17.

    Scharfen COSneed PKWara WMet al: High activity iodine-125 interstitial implant for gliomas. Int J Radiat Oncol Biol Phys 24:5835911992Scharfen CO Sneed PK Wara WM et al: High activity iodine-125 interstitial implant for gliomas. Int J Radiat Oncol Biol Phys 24:583–591 1992

    • Search Google Scholar
    • Export Citation
  • 18.

    Sneed PKGutin PHLarson DAet al: Patterns of recurrence of glioblastoma multiforme after external irradiation followed by implant boost. Int J Radiat Oncol Biol Phys 29:7197271994Sneed PK Gutin PH Larson DA et al: Patterns of recurrence of glioblastoma multiforme after external irradiation followed by implant boost. Int J Radiat Oncol Biol Phys 29:719–727 1994

    • Search Google Scholar
    • Export Citation
  • 19.

    Sneed PKLamborn KRLarson DAet al: Demonstration of brachytherapy boost dose-response relationships in glioblastoma multiforme. Int J Radiat Oncol Biol Phys 35:37441996Sneed PK Lamborn KR Larson DA et al: Demonstration of brachytherapy boost dose-response relationships in glioblastoma multiforme. Int J Radiat Oncol Biol Phys 35:37–44 1996

    • Search Google Scholar
    • Export Citation
  • 20.

    Sneed PKMcDermott MWGutin PH: Interstitial brachytherapy procedures for brain tumors. Semin Surg Oncol 13:1571661997Sneed PK McDermott MW Gutin PH: Interstitial brachytherapy procedures for brain tumors. Semin Surg Oncol 13:157–166 1997

    • Search Google Scholar
    • Export Citation
  • 21.

    Stubbs JBFrankel RHSchultz Ket al: Preclinical evaluation of a novel device for delivering brachytherapy to the margins of resected brain tumor cavities. J Neurosurg 96:3353432002Stubbs JB Frankel RH Schultz K et al: Preclinical evaluation of a novel device for delivering brachytherapy to the margins of resected brain tumor cavities. J Neurosurg 96:335–343 2002

    • Search Google Scholar
    • Export Citation
  • 22.

    Stubbs JBStrickland ADFrank RKet al: Biodistribution and dosimetry of an aqueous solution containing sodium 3-(125I)iodo-4-hydroxybenzenesulfonate (Iotrex) for brachytherapy of resected malignant brain tumors. Cancer Biother Radiopharm 15:6456562000Stubbs JB Strickland AD Frank RK et al: Biodistribution and dosimetry of an aqueous solution containing sodium 3-(125I)iodo-4-hydroxybenzenesulfonate (Iotrex) for brachytherapy of resected malignant brain tumors. Cancer Biother Radiopharm 15:645–656 2000

    • Search Google Scholar
    • Export Citation
  • 23.

    Videtic GMGaspar LEZamorano Let al: Use of the RTOG recursive partitioning analysis to validate the benefit of iodine-125 implants in the primary treatment of malignant gliomas. Int J Radiat Oncol Biol Phys 45:6876921999Videtic GM Gaspar LE Zamorano L et al: Use of the RTOG recursive partitioning analysis to validate the benefit of iodine-125 implants in the primary treatment of malignant gliomas. Int J Radiat Oncol Biol Phys 45:687–692 1999

    • Search Google Scholar
    • Export Citation
  • 24.

    Wallner KEGalicich JHKrol Get al: Patterns of failure following treatment for glioblastoma multiforme and anaplastic astrocytoma. Int J Radiat Oncol Biol Phys 16:140514091989Wallner KE Galicich JH Krol G et al: Patterns of failure following treatment for glioblastoma multiforme and anaplastic astrocytoma. Int J Radiat Oncol Biol Phys 16:1405–1409 1989

    • Search Google Scholar
    • Export Citation
  • 25.

    Wen PYAlexander E IIIBlack PMet al: Long term results of stereotactic brachytherapy used in the initial treatment of patients with glioblastomas. Cancer 73:302930361994Wen PY Alexander E III Black PM et al: Long term results of stereotactic brachytherapy used in the initial treatment of patients with glioblastomas. Cancer 73:3029–3036 1994

    • Search Google Scholar
    • Export Citation
TrendMD
Cited By
Metrics

Metrics

All Time Past Year Past 30 Days
Abstract Views 162 158 9
Full Text Views 197 109 2
PDF Downloads 107 51 0
EPUB Downloads 0 0 0
PubMed
Google Scholar